The cancer immunotherapy space has no lack of PD-1/L1 immune checkpoint inhibitors, from the Opdivo (nivolumab) and Keytruda (pembrolizumab) juggernauts to more niche players like Sanofi US and Regeneron Pharmaceuticals, Inc.’s Libtayo (cemiplimab), but the lineup nonetheless is poised to expand even more in 2021. One just got approved by the US FDA, three novel PD-1/L1 inhibitors are under review, and more are advancing through pivotal trials.
PD-1 Inhibitor Market Poised For A New Round Of Expansion: After GSK’s Jemperli Approval, US FDA Still Has Three Novel Candidates Under Review
Agenus’ recent submission of balstilimab joins novel checkpoint inhibitors from Incyte expecting FDA action this year; Junshi and Coherus’ ongoing rolling BLA for toripalimab is the first from the multiple PD-1/L1 inhibitor candidates developed in China that are vying to enter the US market.
